Melatonin prevents retinal oxidative stress and vascular changes in diabetic rats

Eye (Basingstoke)

Volumn 28, Issue 8, 2014, Pages 1020-1027

  Ozdemir G ^a   Ergun Y ^a   Bakaris S ^a   Kilinc M ^a   Durdu, H ^a   Ganiyusufotlu E ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CD31 ANTIGEN; HEMOGLOBIN A1C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MALONALDEHYDE; MELATONIN; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN A; 3-NITROTYROSINE; ANTIOXIDANT; EYE PROTEIN; HIF1A PROTEIN, RAT; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RETINA BLOOD VESSEL; WISTAR RAT;

ANIMALS; ANTIGENS, CD31; ANTIOXIDANTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; HYPERGLYCEMIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INJECTIONS, INTRAPERITONEAL; MALE; MALONDIALDEHYDE; MELATONIN; NERVE GROWTH FACTORS; OXIDATIVE STRESS; RATS; RATS, WISTAR; RETINAL VESSELS; SERPINS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906246528     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.127     Document Type: Article

References (31)

1. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002; 16: 242-260.
2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS et al. Diabetic retinopathy. Seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55: 2401-2411.
3. Du Y, Smith MA, Miller CM, Kern TS. Diabetes induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80: 771-779.
4. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis. Eye 2009; 23: 1496-1508.
5. Frank RN. Diabetic retinopathy. N Eng J Med 2004; 350: 48-58.
6. Kowluru RA, Menon B, Gierhart DL. Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rats. Invest Ophthalmol Vis Sci 2008; 49: 1645-1651.
7. Salido EM, Bordone M, De Laurentiis A, Chianelli M, Keller Sarmiento MI, Dorfman D et al. Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. J Pineal Res 2013; 54: 179-189.
8. Anwar MM, Meki AR. Oxidative stress in streptozotocin induced diabetic rats: effects of garlic oil and melatonin. Comp Biochem Physiol A 2003; 135: 539-547.
9. Hofman P, van Blijswijk BC, Gaillard PJ, GFJM Vrensen, Schlingemann RO. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina. New insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol 2001; 119: 861-866.
10. Masuzawa K, Jesmin S, Maeda S, Zaedi S, Shimojo N, Miyauchi T et al. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp Biol Med (Maywood) 2006; 23: 1090-1094.
11. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
12. Lowry OH, Rosebrough NJ, Farr AL, Randaii RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
13. Schlingemann RO, Hofman P, GFJM Vrensen, Blaauwgeers HGT. Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage. Diabetologia 1999; 42: 596-602.
14. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162: 1995-2004.
15. Ellis EA, Guberski DL, Hutson B, Grant MB. Time course of NADH Oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR Rat. Nitric Oxide 2002; 6: 295-304.
16. Y?lmaz G, Esser P, Kociek N, Ayd?n P, Heimann K. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2000; 130: 87-90.
17. Witmer AN, GFJM Vrensen, van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
18. Arnal E, Miranda M, Johnsen-Soriano S. Beneficial effect of docosahexanoic acid and lutein on retinal structural, metabolic, and functional abnormalities in diabetic rats. Curr Eye Res 2009; 34: 928-938.
19. Hardy P, Dumont I, Bhattacharya M, Hou X, Lachapelle P, Varma DR et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res 2000; 47: 489-509.
20. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes 2011; 60: 9-16.
21. Huang H, Wang Z, Weng SJ, Sun XH, Yang XL. Neuromodulatory role of melatonin in retinal information processing. Prog Retin Eye Res 2013; 32: 64-87.
22. Tosini G, Iuvone PM, Boatright JH. Is the melatonin receptor type 1 involved in the pathogenesis of glaucoma. J Glaucoma 2013; 22: S49-S50.
23. Jiang T, Chang Q, Zhao Z, Yan S, Wang L, Cai J et al. Melatonin mediated cytoprotection against hyperglycemic injury in Mü ller cells. PLoS One 2012; 7: e50661.
24. Maritim AC, Moore BH, Sanders RA, Watkins JB III. Effects of melatonin on oxidative stres in stretozotocin induced diabetic rats. Int J Toxicol 1999; 18: 161-166.
25. Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res 2012; 103: 82-89.
26. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factor. Exp Eye Res 2006; 83: 473-483.
27. Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006; 51: 364-380.
28. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27: 331-371.
29. Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46: 394-400.
30. Wang B, Atherton P, Patel R, Manning G, Donnelly R. Antiangiogenic effects and transcriptional regulation of PEDF in diabetic retinopathy. Microvasc Res 2010; 80: 31-36.
31. Matsuoka M, Ogata N, Minamino K, Higuchi A, Matsumura M. High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes. Exp Eye Res 2006; 82: 172-178.